Skip to content
Snippets Groups Projects
Commit c100f720 authored by Jean c's avatar Jean c
Browse files

add relevantAbstract in frontmatter

parent 2046f53f
No related branches found
No related tags found
1 merge request!187fix cif path2
Pipeline #120285 passed
Showing
with 59 additions and 0 deletions
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF16872
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiC
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF07751
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiD
......
......@@ -10,6 +10,10 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF08843, PF09407, PF09952, PF11459, PF13338, PF17194
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
- doi: 10.1093/nar/gkt1419
---
# AbiE
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF10899, PF16873
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiG
......
......@@ -9,6 +9,9 @@ tableColumns:
Sensor: Unknown
Activator: Unknown
Effector: Unknown
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiI
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF14355
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiJ
......
......@@ -10,6 +10,10 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF00078
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
- doi: 10.1093/nar/gkac467
---
# AbiK
......
......@@ -9,6 +9,9 @@ tableColumns:
Sensor: Unknown
Activator: Unknown
Effector: Unknown
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiN
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF01443, PF09848
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiO
......
......@@ -10,6 +10,10 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF00078
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
- doi: 10.1093/nar/gkac467
---
# AbiP2
......
......@@ -10,6 +10,10 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF13958
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
- doi: 10.1128/AEM.64.12.4748-4756.1998
---
# AbiQ
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF00176, PF00271, PF04545, PF04851, PF13091
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiR
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF18864
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1016/j.mib.2005.06.006
---
# AbiT
......
......@@ -10,6 +10,9 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF18728
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1128/AEM.00780-08
---
# AbiV
......
......@@ -9,6 +9,9 @@ tableColumns:
Sensor: Unknown
Activator: Unknown
Effector: Membrane disrupting
relevantAbstracts:
- doi: 10.1023/A:1002027321171
- doi: 10.1128/JB.00904-06
---
# AbiZ
......
......@@ -10,6 +10,8 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF18928
relevantAbstracts:
- doi: 10.1016/j.chom.2022.09.017
---
# Aditi
......
......@@ -10,6 +10,8 @@ tableColumns:
Activator: Unknown
Effector: Unknown
PFAM: PF00271
relevantAbstracts:
- doi: 10.1016/j.chom.2022.09.017
---
# Azaca
......
......@@ -9,6 +9,8 @@ tableColumns:
Sensor: Unknown
Activator: Unknown
Effector: Unknown
relevantAbstracts:
- doi: 10.1016/j.chom.2021.09.002
---
# BstA
......
......@@ -6,6 +6,8 @@ tableColumns:
doi: 10.1101/2023.01.03.522681
abstract: |
During lysogeny temperate phages establish a truce with the bacterial host. In this state, the phage genome (prophage) is maintained within the host environment. Consequently, many prophages have evolved systems to protect the host from heterotypic viral attack. This phenomenon of prophages mediating defense of their host against competitor phages is widespread among temperate mycobacteriophages. We previously showed that the Mycobacterium phage Butters prophage encodes a two-component system (gp30/31) that inhibits infection from a subset of mycobacteriophages that include PurpleHaze, but not Island3. Here we show that Butters gp57r is both necessary and sufficient to inhibit infection by Island3 and other phages. Gp57r acts post-DNA injection and its antagonism results in the impairment of Island3 DNA amplification. Gp57r inhibition of Island3 is absolute with no defense escape mutants. However, mutations mapping to minor tail proteins allow PurpleHaze to overcome gp57r defense. Gp57r has a HEPN domain which is present in many proteins involved in inter-genomic conflicts, suggesting that gp57r may inhibit heterotypic phage infections via its HEPN domain. We also show that Butters gp57r has orthologues in clinical isolates of Mycobacterium abscessus sp. including the phage therapy candidate strain GD91 which was found to be resistant to the panel of phages tested. It is conceivable that this GD91 orthologue of gp57r may mediate resistance to the subset of phages tested. Challenges of this nature underscore the importance of elucidating mechanisms of antiphage systems and mutations that allow for escape from inhibition. IMPORTANCE The evolutionary arms race between phages and their bacteria host is ancient. During lysogeny, temperate phages establish a ceasefire with the host where they do not kill the host but derive shelter from it. Within the phenomenon of prophage-mediated defense, some temperate phages contribute genes that make their host more fit and resistant to infections by other phages. This arrangement has significance for both phage and bacterial evolutionary dynamics. Further, the prevalence of such antiphage systems poses a challenge to phage therapy. Thus, studies aimed at elucidating antiphage systems will further our understanding of phage-bacteria evolution as well as help with efforts to engineer therapeutic phages that circumvent antiphage systems.
relevantAbstracts:
- doi: 10.1101/2023.01.03.522681
---
# Butters_gp57r
......
......@@ -10,6 +10,8 @@ tableColumns:
Activator: Direct
Effector: Nucleic acid degrading (pyrophosphorylates tRNAs)
PFAM: PF04607
relevantAbstracts:
- doi: 10.1038/s41586-022-05444-z
---
# CapRel
......
0% Loading or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment